Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Asset Writedowns and Impairment (2016 - 2025)

Guided Therapeutics' Asset Writedowns and Impairment history spans 5 years, with the latest figure at $2000.0 for Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $2000.0; the TTM value through Sep 2025 reached $1000.0, up 200.0%, while the annual FY2022 figure was $23000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q3 2025 was $2000.0 at Guided Therapeutics, up from -$1000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2000.0 in Q3 2025 and bottomed at $2000.0 in Q3 2025.